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COVID-19
●

January 11, 2020
○

●

Publication of the genetic sequence of SARS-CoV-2
■ Led to the rapid development of vaccine for the virus

About two months later…
○

March 16, 2020
■ The ﬁrst COVID-19 vaccine began human clinical trials

The Coalition for Epidemic Preparedness Innovations
(CEPI)
●
●
●

Headquarters in Oslo, Norway
A global coalition consisting of public, private, and philanthropic
organizations
Support and fund acceleration of vaccine development during epidemic
diseases

April 8, 2020
●

COVID-19 VACCINES
○

●

115 Vaccine Candidates
■ 78 are conﬁrmed and active
● 73 of which are currently in preclinical or exploratory stages
■ 37 unconﬁrmed
■ Many vaccine developers plan for human testing trials in 2020

Current Vaccines in Clinical Development
○
○
○
○

Moderna: mRNA-1273
■ Began clinical testing 2 months after sequence identiﬁcation
CanSino Biologicals: Ad5-nCoV
Inovio: INO-4800
Shenzhen Geno-Immune Medical Institute: LV-SMENP-DC and pathogen-speciﬁc aAPC

Diversity in Vaccine Development Platforms
●

Technology platforms include…
○
○
○
○
○
○

●

Nucleic Acid (DNA/RNA)
Virus-Like Particle
Peptide
Viral Vector (replicating and non-replicating)
Recombinant Protein
Live attenuated virus and inactivated virus approaches

It is possible that some vaccines may be most eﬀective
with speciﬁc populations such as elderly, pregnant
women, and children

Analysis of Current Vaccine Platforms
●

Vaccines focused on DNA or mRNA
○

●

Vaccines based on Viral Vectors
○

●

oﬀers promising versatility of antigen manipulation & speed
long-term stability, high level of protein expression, and
induces strong immune responses

Vaccines based on Recombinant Proteins
○
○

Previously licensed vaccines for other diseases
Pro: ability for large scale production due to the existing
vaccines

Adjuvants
Deﬁnition: substances that may be added to a vaccine in order to produce a
strong immune response to the vaccine
●

Pros: potential for lower viable doses & enhance immunogenicity

●

GlaxoSmithKline, Seqirus, Dynavax

Speciﬁcs in SARS-CoV-2 Vaccine Development
●

Information about the speciﬁc antigens being used in vaccine
development is limited
○

●

Available information describes the induction of neutralizing antibodies against the viral
spike (S) protein, preventing uptake via the human ACE2 receptor

Current research has not yet determined how the S protein relates to its
various other forms and COVID-19

72% - private/industry developers
28% - academic, public sector, and other non-proﬁt organizations
46% - developers in North America

18% - China

18% - Asia (excluding China)

18% - Europe

Conclusion
●

Possible vaccines may be available by early 2021
○

●

Average vaccine development usually takes around 10 years
○

●

Emergency use ONLY
Ebola Virus : 5 year development of a vaccine

Development of COVID-19 Speciﬁc Animal Models
○
○
○
○

ACE2-transgenic mice
Hamsters
ferrets
non-human primates

Discussion Questions
●
●

Is it more likely for developers in another country, such as China, to
ﬁnalize a vaccine before the US?
How do you think the current lack of a vaccine will aﬀect the rate of the
spread of the virus?
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